THERAPEUTIC POTENTIAL OF THE LHRH AGONIST, ICI 118630, IN THE TREATMENT OF ADVANCED PROSTATIC CARCINOMA
- 1 August 1983
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 322 (8347), 413-415
- https://doi.org/10.1016/s0140-6736(83)90386-0
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- SUSTAINED SUPPRESSION OF TESTOSTERONE PRODUCTION BY THE LUTEINISING-HORMONE RELEASING-HORMONE AGONIST BUSERELIN IN PATIENTS WITH ADVANCED PROSTATE CARCINOMAThe Lancet, 1982
- Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult menFertility and Sterility, 1982
- Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.Proceedings of the National Academy of Sciences, 1982
- Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.Proceedings of the National Academy of Sciences, 1981
- Recent Approaches to Fertility Control Based on Derivatives of LH-RHPublished by Elsevier ,1981
- Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonistBritish Journal of Cancer, 1979
- Inhibitory Effect of LHRH and Its Agonists on Testicular Gonadotrophin Receptors and Spermatogenesis in the RatInternational Journal of Andrology, 1978
- Hypothalamic Regulatory HormonesAnnual Review of Biochemistry, 1978
- Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist or human chorionic gonadotropinBiochemical and Biophysical Research Communications, 1977
- Endocrine-Dependent Rat Mammary Tumor Regression: Use of a Gonadotropin Releasing Hormone AnalogScience, 1976